[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Oh SY, Kim WS, Kim SJ, Kim JS, Kim SH, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Kim JG, Yang DH, Kang HJ, Choi CW, Park J, Choi YJ, Kim HJ, Kwon JH, Suh C, Kim HJ: Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol; 2009 Dec;84(12):826-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
  • Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses.
  • The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%).
  • The median time to relapse from initial diagnosis was 25.5 months.
  • Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence.
  • In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse.
  • Among those patients with advanced stage at relapse, 44 patients were treated.
  • The median time to progression (TTP) was 34.1 months (95% CI: 11.3-56.9 months) and the estimated 5-year overall survival (OS) was 84.3%.
  • The majority of them was controlled well with salvage treatment, and could achieve prolonged survival.
  • However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS.
  • Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Orbital Neoplasms / epidemiology. Orbital Neoplasms / pathology. Orbital Neoplasms / therapy. Prognosis. Recurrence. Republic of Korea / epidemiology. Retrospective Studies. Salvage Therapy. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19890833.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Ke X, Jing H, Li M, An X, Gao Z: [Analysis of 37 pathological and clinic data of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)]. Beijing Da Xue Xue Bao; 2003 Apr 18;35(2):123-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 37 pathological and clinic data of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)].
  • OBJECTIVE: To provide pathological and clinical evidences in order to establish standardized diagnosis and treatment for MALT lymphoma.
  • METHODS: Pathological characters, grade, stage, prognostic factors and treatment of 37 cases of MALT lymphoma were analyzed which were diagnosed from January 2000 to June 2002.
  • RESULTS: The 39 patients(8.82%) were diagnosed as MALT lymphoma out of 442 NHL patients(37 patients were followed up, and two missing).
  • Among 28 (71.8%) of 37 patients with gastro-intestinal(GI) Maltoma, low-grade was 70.3%, median-grade 27.0%, stage I 53.6%, stage II 28.6%, stage III 14.3%, and stage IV 3.6%.
  • Of phenotype 35 cases were CD20 positive, and 4 cases were diagnosed as MALT lymphoma supported by PCR detecting IgH re-arrangement.
  • Patients with GI MALT lymphoma received 3-cycle antibiotic treatment.
  • Most of patients received chemotherapy, with 4 plus local radiotherapy.
  • Only one patient received antibiotic treatment alone.
  • No one received radiation treatment alone.
  • CONCLUSION: MALT lymphoma was often seen in older patients, most of whom were in low-grade with slow disease progression.
  • The site, grade, stage and molecular genetic change are important prognostic factors, which can help us to make decision in choosing suitable treatment.
  • [MeSH-major] Helicobacter Infections. Lymphoma, B-Cell, Marginal Zone / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12920824.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, Tarella C, Vitolo U, Zinzani PL, Tura S: Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica; 2005 Sep;90(9):1236-57
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation.
  • The Italian Society of Hematology (SIE) and the two affiliated societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal indolent non-Hodgkin's lymphomas (NHL).
  • After a comprehensive, systematic review of the literature, the Expert Panel formulated therapy recommendations and graded them according to the supporting evidence.
  • The Expert Panel formulated recommendations on when to start a lymphoma-specific therapy, which first-line therapy to choose and which therapy to adopt for patients with relapsed, refractory and transformed disease.
  • Treatment deferral was recommended for patients with stage III-IV disease without systemic symptoms, high tumor burden, extranodal disease, cytopenia due to marrow involvement, leukemic phase, serous effusion and high lactate dehydrogenase levels.
  • Patients with stage I-II disease and a low tumor burden should receive frontline external involved-field radiotherapy, while patients with a high tumor burden or a severe prognostic score should receive front-line chemotherapy plus involved-field radiotherapy.
  • Younger patients with stage III-IV disease should receive front-line therapy with anthracycline- or fludarabine-based regimens combined with rituximab, while older patients who are candidates for treatment should receive single-agent alkylating therapy.
  • By using a systematic literature review and an explicit approach to consensus among experts, recommendations for the key therapeutic decisions in patients with nodal indolent NHL are provided.
  • [MeSH-major] Bone Marrow Transplantation / standards. Hematology / standards. Lymphoma, Non-Hodgkin / therapy. Practice Guidelines as Topic / standards. Societies, Medical / standards

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16154848.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


Advertisement
4. Oh SY, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C: Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs; 2010 Apr;28(2):171-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
  • BACKGROUND: Therapeutic approaches to marginal zone B-cell lymphoma (MZL) continue to evolve.
  • Localized MZL responds favorably to local treatments, including surgery and/or local radiation therapy.
  • Moreover, relapses involving distant sites after local therapy have been reported previously.
  • Therefore, the search for effective forms of systemic therapy is a critical issue.
  • We conducted this multi-center, phase II trial to assess the efficacy and safety of gemcitabine single chemotherapy for patients with stage III/IV MZL.
  • The treatment was repeated every 3 weeks and continued for 6 cycles until disease progression, withdrawal due to toxicity, or withdrawal of consent.
  • All patients received previous treatment for MZL.
  • The patients received a total of 69 cycles of gemcitabine chemotherapy (range 3-6 [median 6] cycles/person).
  • There were 5 cycles (8%) of delayed chemotherapy (median 1 week) owing to neutropenia.
  • However, no treatment-related death occurred in this study.
  • As the response rate in stage I did not justify progressing to stage II (> or = 8/15), this study had to be discontinued, in accordance with the established protocols.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cooperative Behavior. Deoxycytidine / analogs & derivatives. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):47-53 [7481845.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3192-8 [18932253.001]
  • [Cites] Eur J Haematol. 2008 Feb;80(2):127-32 [18005385.001]
  • [Cites] Cancer. 2004 May 15;100(10):2190-4 [15139063.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4349-57 [9766663.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3349-52 [15867234.001]
  • [Cites] Am J Hematol. 2007 Jun;82(6):446-52 [17266060.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv18-24 [16702180.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Cancer Treat Rev. 2009 Jun;35(4):335-9 [19131170.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):772-8 [11380469.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1835-42 [15386331.001]
  • [Cites] Breast Cancer Res Treat. 2008 Apr;108(3):319-31 [17530427.001]
  • [Cites] Adv Exp Med Biol. 2000;486:287-90 [11783501.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(15):1974-83 [11000580.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):883-9 [18452104.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4138-43 [8033147.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8442-6 [16293875.001]
  • [Cites] Haematologica. 2000 Sep;85(9):926-9 [10980630.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18 Suppl):23S-33S [12235221.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2524-9 [7595703.001]
  • [Cites] Exp Hematol. 1998 Dec;26(13):1223-8 [9845378.001]
  • [Cites] Hematology. 2007 Apr;12(2):149-53 [17454196.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):165-8 [15803011.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3786-92 [10577850.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):78-85 [10444166.001]
  • [Cites] Int J Hematol. 2004 May;79(4):311-21 [15218957.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1382-91 [14630277.001]
  • [Cites] Best Pract Res Clin Haematol. 2005 Mar;18(1):57-68 [15694184.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):169-72 [15803012.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16 [19219604.001]
  • (PMID = 19421710.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


5. Liu MT, Hsieh CY, Wang AY, Pi CP, Chang TH, Huang CC, Huang CY: Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases. Ann Saudi Med; 2005 Jul-Aug;25(4):288-93
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases.
  • BACKGROUND: Primary breast lymphoma is a rare disease.
  • We conducted a pooled analysis to evaluate the treatment outcome and prognostic factors in patients with primary breast lymphoma.
  • Treatments included single therapy or combined surgery, chemotherapy and radiotherapy.
  • We analyzed the correlation between treatment protocols, tumor relapse and survival.
  • Histopathology and cancer stage were analyzed to evaluate their significance in treatment outcome.
  • The histopathology of 63 patients (68%) was diffuse large cell lymphoma.
  • According to Ann Arbor classification, 57% were stage I, 23% were stage II, 4% were stage III, and 16% were stage IV.
  • Thirteen percent received surgery alone, 27% received chemotherapy alone, 7% received radiotherapy alone, 10% received surgery and chemotherapy, 10% received surgery and radiotherapy, 22% received chemotherapy and radiotherapy, and 11% received surgery combined with chemotherapy and radiotherapy.
  • The mean time to first tumor relapse after treatment was 20 months.
  • Tumor stage was a significant prognostic factor affecting overall survival, disease-free survival and disease-specific survival (P=0.0231, 0.0015, 0.0124, respectively).
  • Patients who received chemotherapy and radiotherapy had better survival outcome and a lower relapse rate.
  • We suggestthat chemotherapy and radiotherapy be the initial treatment for patients with primary breast lymphoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / therapy. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / epidemiology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16212120.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


6. Hitchcock S, Ng AK, Fisher DC, Silver B, Bernardo MP, Dorfman DM, Mauch PM: Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2002 Mar 15;52(4):1058-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the treatment outcome in patients with mucosa-associated lymphoid tissue (MALT)/marginal zone (MZ) non-Hodgkin's lymphoma (NHL).
  • MATERIALS AND METHODS: Between 1986 and 2000, 66 patients with clinical stage (CS) I-IV MALT/MZ NHL were treated; these comprise the study population.
  • Forty-five patients (68%) had CS I-II and 21 (32%) had CS III-IV disease.
  • Twenty-nine of the 45 CS I-II patients received radiation therapy (RT) alone, and 6 patients had surgery and RT.
  • Among the 21 CS III-IV patients, treatment included chemotherapy alone (15), chemotherapy + RT (3), surgery (1), surgery + chemotherapy (1), and RT alone (1).
  • RESULTS: All 35 early-stage and all 4 advanced-stage patients who received RT as part of initial treatment achieved local control.
  • The 5-year OS was 93% and PFS was 75% among CS I-II patients; the corresponding estimates in CS III-IV patients were 83% and 14%, respectively.
  • The poor PFS in advanced-stage patients suggests the need to develop alternative systemic treatment strategies for this disease.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Conjunctival Neoplasms / mortality. Conjunctival Neoplasms / pathology. Conjunctival Neoplasms / radiotherapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Orbital Neoplasms / mortality. Orbital Neoplasms / pathology. Orbital Neoplasms / radiotherapy. Parotid Neoplasms / mortality. Parotid Neoplasms / pathology. Parotid Neoplasms / radiotherapy. Recurrence. Stomach Neoplasms / pathology. Stomach Neoplasms / radiotherapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11958902.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Radman I, Kovacević-Metelko J, Aurer I, Nemet D, Zupancić-Salek S, Bogdanić V, Sertić D, Mrsić M, Pulanić R, Gasparović V, Labar B: Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study. Croat Med J; 2002 Oct;43(5):555-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.
  • AIM: To evaluate the role of surgical resection in the treatment of patients with primary gastrointestinal non-Hodgkin s lymphoma in our institution.
  • METHOD: The retrospective study included 79 patients with a histologically confirmed primary gastrointestinal lymphoma, who were diagnosed and treated for the disease in the 1978-1997 period.
  • According to the treatment modality, the patients were divided into surgically treated and surgically non-treated group.
  • RESULTS: The stomach was the primary site of non-Hodgkin s lymphoma in 45 (57%) patients, small intestine in 19 (24%), and colon in 9 (11%) patients.
  • There were 56 (71%) patients with stages IE and IIE, and 23 (29%) with stages III and IV.
  • Aggressive histology was found in 51 cases (65%), and low grade mucosa-associated lymphoid tissue (MALT) lymphoma in 28 (35%).
  • Helicobacter pylori infection was registered in 20 out of 45 patients with gastric lymphoma.
  • Twenty-six (33%) patients underwent surgical resection followed by chemotherapy, 47 (59%) were treated with chemotherapy alone, and 6 (8%) received antibiotics plus chemotherapy.
  • Patients with gastric lymphoma had better OS and EFS than patients with primary lymphoma at other sites (65% vs 42%, and 62 vs 28%, respectively) (p=0.005).
  • Patients with early-stage disease had significantly better OS and PFS than patients with advanced-stage disease (p=0.048).
  • CONCLUSION: Primary gastrointestinal lymphoma can be successfully treated with chemotherapy alone but surgery remains an important therapeutic option for emergency problems.
  • [MeSH-major] Colonic Neoplasms / surgery. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402395.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


8. Traverse-Glehen A, Felman P, Callet-Bauchu E, Gazzo S, Baseggio L, Bryon PA, Thieblemont C, Coiffier B, Salles G, Berger F: A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology; 2006 Jan;48(2):162-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases.
  • AIMS: To report the clinicopathological findings of 21 cases of primary nodal marginal zone B-cell lymphoma (NMZL).
  • NMZL is a recently characterized lymphoma and few series have been published.
  • METHODS AND RESULTS: The clinical data were characteristic of a disseminated disease at presentation: presence of peripheral and abdominal lymph nodes, bone marrow involvement (62%), disease stage III and IV (76%), elevated lactate dehydrogenase (LDH) (48%).
  • Relapses were frequent but the majority of patients receiving chemotherapy had a good initial response.
  • Morphological features were heterogeneous and there were some differences compared with other marginal zone B-cell lymphomas (MZL).
  • Pure monocytoid B-cell lymphomas were rare (10%) but a minor component of monocytoid B cell was observed more frequently (23%).
  • [MeSH-major] Lymphoma, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405665.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


9. Hsu C, Chen CL, Chen LT, Liu HT, Chen YC, Jan CM, Liu CS, Cheng AL: Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: does histologic evidence of MALT affect chemotherapy response? Cancer; 2001 Jan 1;91(1):49-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: does histologic evidence of MALT affect chemotherapy response?
  • BACKGROUND: Although the clinicopathologic features of low grade gastric MALToma (lymphoma of mucosa-associated lymphoid tissue) recently have been well delineated, the significance of identifying histologic evidence of MALT origin in a primary high grade gastric lymphoma is less clear.
  • The authors sought to address this issue and, in particular, to clarify if MALT and non-MALT primary large cell gastric lymphoma might have a different response to systemic chemotherapy.
  • METHODS: The authors reviewed the pathologic specimens of all patients who had a diagnosis of primary large cell lymphoma of the stomach and who had been treated primarily by systemic chemotherapy in our institutions January 1, 1988-December 31, 1998.
  • All patients received standard systemic chemotherapy including anthracyclines or anthracenedione.
  • Multivariate analysis indicated that response to chemotherapy, disease stage (Stage I and II-1 vs. Stage II-2, III, and IV), and the presence of MALToma features were independent prognostic factors for overall survival.
  • CONCLUSION: The results of this relatively small study series suggested that the presence of histologic features of MALToma in patients with primary large cell gastric lymphoma might have been associated with a better response to systemic chemotherapy and a better prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11148559.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW: Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol; 2009 Apr;20(4):709-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
  • BACKGROUND: To determine the efficacy and side-effects of (90)Y ibritumomab tiuxetan (Zevalin) as front-line treatment in patients with early-stage extranodal indolent lymphoma of the ocular adnexa (orbit, conjunctiva, or eyelid).
  • PATIENTS AND METHODS: From August 2004 to November 2007, 12 patients with stages I-E extranodal indolent lymphoma of the ocular adnexa were enrolled in a prospective trial of rituximab followed by (90)Y ibritumomab tiuxetan (Zevalin therapeutic regimen).
  • For each patient, clinical examinations and imaging studies were used to document response to therapy using the The International Working Group response criteria.
  • All patients had (111)In ibritumomab tixuetan imaging to confirm expected biodistribution before (90)Y-Zevalin therapy; in addition, three patients had an optional single photon emission computed tomography-computed tomography scan to estimate the absorbed radiation dose to the orbital and ocular tissues.
  • Nine patients had mucosa-associated lymphoid tissue lymphoma of conjunctiva or orbit; three patients had grades 1-2 follicular lymphoma of orbit.
  • One patient who had been deemed stage I-E initially was found to have another lesion in her deltoid muscle on positron emission tomography 2 weeks after enrollment.
  • She was kept on trial although her disease was reclassified as stage IV due to this single additional (biopsy-proven) site.
  • Ten patients had a complete response and two partial response (PR) within 3 months of treatment.
  • One patient had a recurrence in the upper eyelid 6 months after an initial PR; he then received 30 Gy of external-beam radiotherapy (EBRT).
  • His disease later progressed again in the orbit and he is currently being considered for other treatments.
  • A second patient who attained a PR has remained stable with no progression 12 months after treatment.
  • With a median follow-up time of 20 months (range 6-44 months), there were no cases of distant (extraorbital) relapse.
  • There were no episodes of grade III or IV myelosuppression.
  • The estimated absorbed radiation dose to the orbital soft tissues was <3 Gy, 10 times lower than that with EBRT.
  • CONCLUSIONS: Rituximab followed by (90)Y ibritumomab tiuxetan is an effective and safe front-line treatment for early-stage extranodal indolent B-cell lymphoma of the ocular adnexa.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150940.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


11. Ogura M: [Recent progress in the treatment of malignant lymphoma]. Gan To Kagaku Ryoho; 2001 Sep;28(9):1213-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent progress in the treatment of malignant lymphoma].
  • The present state of the art and developments in the treatment for Hodgkin's disease (HD), follicular lymphoma (FL), MALT lymphoma, and aggressive non-Hodgkin's lymphoma are reviewed.
  • Four courses of ABVD therapy (ABVd therapy in Japan) followed by involved-field irradiation (IFRT), and 6 to 8 courses of ABVD (ABVd in Japan) are the current state art of the therapy for early stage HD and advanced stage HD, respectively.
  • High-dose chemotherapy with autologous hematopoietic stem cell transplantation (auto-HSCT) is also the state of the art for refractory or relapsed HD within 1 year after complete remission (CR) produced by polychemotherapy.
  • New intensified polychemotherapy or auto-HSCT as up-front setting is under randomized phase III clinical trial in Europe and the USA.
  • There is no state of the art therapy for indolent lymphoma including FL, or MALT.
  • Promising results were reported from clinical studies using new anti-lymphoma drugs such as rituximab, iibritumomab, or purine analogs (cladribine and fludarabine), and auto-HSCT with effectively purged stem cells or allogeneic HSCT.
  • These therapeutic strategies hold a possibility of cure for indolent lymphomas.
  • Antibiotic treatment for Helicobacter pylori-positive localized gastric MALT lymphoma is the state of the art therapy.
  • However, there is no standard therapy for advanced stage MALT lymphoma.
  • Risk adapted therapy using the International Prognostic Index is essential for the treatment of aggressive NHL.
  • Three courses of CHOP followed by IFRT for localized aggressive NHL and 8 courses of CHOP for the low-risk group of advanced stage aggressive NHL are the state of the art therapies, respectively.
  • High-dose chemotherapy with auto-HSCT is also the state of the art for sensitive relapse patients with aggressive NHL.
  • Although some clinical studies suggested that high-dose chemotherapy with auto-HSCT as up-front setting for high-intermediate or high-risk group aggressive NHL is more effective than conventional chemotherapy, the efficacy remains to be determined.
  • The development of new therapeutic strategies with combined use of molecular targeting drugs such as rituximab, or new anti-lymphoma drugs such as purine analogs, and HSCT is desired for more effective therapy for refractory lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma / therapy
  • [MeSH-minor] Clinical Trials as Topic. Helicobacter Infections / drug therapy. Helicobacter pylori. Hematopoietic Stem Cell Transplantation. Humans. Leukemia, Lymphoid / therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Non-Hodgkin / therapy. Prognosis. Radioimmunotherapy. Recurrence

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579632.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 77
  •  go-up   go-down


12. Dunn P, Kuo TT, Shih LY, Lin TL, Wang PN, Kuo MC, Tang CC: Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan. Acta Haematol; 2004;112(4):203-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary salivary gland lymphoma: a clinicopathologic study of 23 cases in Taiwan.
  • Twenty-three patients with primary salivary gland lymphoma were diagnosed between 1990 and 2001.
  • The sites of lymphoma involvement beyond the salivary glands were the cervical lymph nodes in 7, bone marrow in 3, the axillary lymph nodes in 3, the nasopharynx in 2, the abdominal lymph nodes in 2, the palate, the subconjunctiva, and the spleen in 1 each patient.
  • Histologically, 19 patients had lymphomas of mucosa-associated lymphoid tissue (MALT) with myoepithelial sialadenitis in 13, 3 patients had diffuse large cell lymphomas and 1 had follicular lymphoma.
  • Six patients were in stage I, 4 in II, 1 in III and 12 in IV.
  • Eight of 23 patients (35%) had autoimmune diseases before or after the diagnosis of NHL and all suffered from MALT lymphoma.
  • Four patients with parotid MALT lymphoma had primary or secondary Sjogren's syndrome.
  • All the 6 stage I patients had achieved complete remission (CR) without relapses 17-84 months (median 44 months) after treatment.
  • Excluding a stage IV patient with follicular lymphoma who died at 3.5 months without treatment, CR was achieved in all of the remaining 16 patients.
  • However, a high relapse rate (9/16, 56%) was noted in stage II-IV patients.
  • These patients tended to relapse in the original sites, but achieved CR again after chemotherapy or radiotherapy.
  • One patient with MALT lymphoma developed histologic transformation into diffuse large lymphoma during relapse and died of refractory disease.
  • Thus, salivary gland lymphoma proved to be an indolent disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Autoimmune Diseases / complications. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / complications. Male. Middle Aged. Radiotherapy. Remission Induction. Survival Rate. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564732.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Zinzani PL, Gandolfi L, Stefoni V, Fanti S, Fina M, Pellegrini C, Montini GC, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M: Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. Clin Lymphoma Myeloma Leuk; 2010 Aug;10(4):258-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
  • BACKGROUND: Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database.
  • PATIENTS AND METHODS: Between 2005 and 2008, 57 patients previously treated with at least 1 rituximab-containing chemotherapy were treated with Yttrium-90-labeled ibritumomab tiuxetan ((90)Y-IT).
  • A total of 46 patients had stage III/IV disease (31 with bone marrow involvement); 6 had bulky disease.
  • According to histology, 53 were follicular lymphoma (FL), 2 were marginal zone lymphoma, and 2 were small lymphocytic lymphoma.
  • All patients achieving a CCR had FL, and 21 of them with stage III/IV disease; 12 of 26 had been heavily pretreated (>or= 3 previous treatments), and 2 had had autologous stem cell transplantation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Time. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20709661.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


14. Cao YB, Wang SS, Huang HQ, Xu GC, He YJ, Guan ZZ, Lin TY: [Primary breast lymphoma--a report of 27 cases with literature review]. Ai Zheng; 2007 Jan;26(1):84-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary breast lymphoma--a report of 27 cases with literature review].
  • BACKGROUND & OBJECTIVE: Primary breast lymphoma (PBL) is an uncommon disease with poor clinical outcome.
  • This study was to investigate clinicopathologic features and optimal treatment of PBL.
  • RESULTS: Of the 27 patients, 26 were women and 1 was man, with the age ranged from 12 to 84; 18 were at stage IE, 6 at stage IIE, and 3 at stage III/IVE; according to the WHO 2001 lymphoma classification system, 22 had B-cell lymphoma (including 17 cases of diffuse large B-cell lymphoma, 2 cases of mucosa-associated lymphoid tissue lymphoma, 1 case of marginal zone lymphoma, and 2 cases of unclassified B-cell lymphoma), 3 had peripheral T-cell lymphoma, and 2 had unclassified lymphoma.
  • Of the 27 patients, 8 received mastectomy and chemotherapy, 12 received excision of the breast lesion and chemotherapy (the 5-year overall survival rates were 23% and 58%, P=0.006), 5 received chemotherapy alone, and 2 received lesion excision alone; 24 achieved complete remission (CR) after scheduled treatment, 1 achieved partial remission (PR), and 2 patients had progressive disease (PD).
  • As to the 20 patients with high or moderate grade diseases (diffuse large B-cell lymphoma and peripheral T-cell lymphoma), the 5-year overall and disease-free survival rates were 48% and 27%, respectively.
  • CONCLUSIONS: The main subtypes of PBL are diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms, Male / therapy. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Mastectomy / methods. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222374.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 14
  •  go-up   go-down


15. Papaxoinis G, Fountzilas G, Rontogianni D, Dimopoulos MA, Pavlidis N, Tsatalas C, Pectasides D, Xiros N, Economopoulos T: Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol; 2008 Apr;19(4):780-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).
  • BACKGROUND: The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Epidemiological and clinical features of 97 patients with MALT lymphoma from the Hellenic Cooperative Oncology Group registry were analysed retrospectively for their prognostic significance in progression-free survival (PFS) and overall survival (OS).
  • Comparisons were made between patients with gastric and nongastric sites of primary lymphoma and between different therapeutic modalities.
  • Seventy-four per cent of patients had early (Ann Arbor stages I-II) and 26% had advanced (stages III-IV) disease.
  • The most reliable prognostic factor for PFS and OS was the Ann Arbor stage; 5-year PFS was 67% versus 13% and 5-year OS 91% versus 51% for patients with early versus advanced disease, respectively (P < 0.001).
  • Of the patients treated with chemotherapy only, 87% achieved an objective response and 71% complete response.
  • Surgery did not offer survival benefit compared with chemotherapy in localised gastric lymphoma.
  • Ann Arbor stage was the most reliable prognostic and predictive factor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156143.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


16. Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A: Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma; 2004 Sep;45(9):1821-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
  • The therapy of patients with relapsed or refractory indolent lymphoma relies on the development of new drug combinations.
  • The drugs bendamustine and fludarabine have cytotoxic activity as monotherapy in indolent lymphoma and show synergism in vitro.
  • In this study, we combined both drugs in a multicenter clinical phase I/II trial to evaluate their toxicity and efficacy.
  • Bendamustine was given at 30 or 40 mg/m2/d (dose levels 1 and 2), fludarabine at 30 mg/m2/d, each drug on days 1 to 3.
  • A total of 29 patients with relapsed or refractory indolent lymphoma were included in the study.
  • Fourteen patients had follicular lymphoma, 11 patients mantle cell lymphoma, 2 patients lymphoplasmocytic and 2 patients nodal marginal zone lymphoma.
  • All patients were in stages III or IV of their disease and had received prior chemotherapy with or without additional radio- or immunotherapy.
  • Analysis of 19 evaluable patients treated at dose level 1 reveiled hematotoxicity CTC grade III in 47% and grade IV in 26%.
  • Nine of 9 patients with mantle cell lymphoma responded to therapy.
  • Eight of 15 responders relapsed after a median follow-up time of 14 months (range 2-43).
  • Dose level 1 with 30 mg/m2/d of both drugs on days 1 to 3 was defined as the recommended dose.
  • Despite unfavorable prognostic features (histologic subtype, stage of disease, pretreatment) response rates were good with this regimen.
  • [MeSH-major] Hematology. Lymphoma / drug therapy. Lymphoma / pathology. Medical Oncology. Nitrogen Mustard Compounds / therapeutic use. Societies, Medical. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Bendamustine Hydrochloride. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Taylor and Francis Ltd
  • (PMID = 15223642.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


17. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM: Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol; 2009 Jul 10;27(20):3346-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
  • PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
  • PATIENTS AND METHODS: Eighty-two patients (median age, 64 years; 79% stage III/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg/m(2) of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity.
  • RESULTS: Veltuzumab was well tolerated, with no grade 3 to 4 drug-related adverse events despite short infusion times (typically 2 hours initially, 1 hour subsequently at doses < 375 mg/m(2)).
  • In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular Lymphoma International Prognostic Index > or = 2), and at all dose levels.
  • In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses.
  • At all dose levels studied, B cells were depleted after the first infusion, veltuzumab serum half-lives were similar after the fourth infusion, and mean antibody serum levels exceeded values considered important for anti-CD20 therapy (ie, 25 microg/mL).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00285428/ NCT00596804
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
  •  go-up   go-down


18. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T: Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma; 2006 Oct;47(10):2140-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG).
  • The aim of this retrospective study was to illustrate the clinicopathologic data and the treatment results in patients with primary gastrointestinal tract non-Hodgkin's lymphoma (GI NHL).
  • Overall, 67.2% of the patients were in stages I - II, and 32.8% in stages III - IV.
  • Extranodal marginal zone B-cell lymphoma (MZBL) (i.e., low-grade lymphoma of mucosa-associated lymphoid tissue type) accounted for 48.4% of lymphomas.
  • Aggressive lymphomas (diffuse large B-cell lymphoma [DLBL]) accounted for 44.5%.
  • Eighty-three patients (67.5%) achieved complete response (CR), either by surgery (43/43 patients, 17 with DLBL and 25 with MZBL) or by primary chemotherapy (40/64 patients, 22 with DLBL and 17 with MZBL).
  • Sixty-two patients remain in CR; 33/43 after surgical resection (13/17 with DLBL and 20/25 patients with MZBL), and 29/40 after only chemotherapy (18/22 with DLBL and 10/17 with MZBL).
  • The major prognostic factor for outcome in the present study was the stage of the disease.
  • Patients with localized lymphoma (stage I and II) had significantly longer DFS and OS (DFS and OS at 3-year: 83% and 87%, respectively) than patients with extended disease (stage III and IV) (DFS and OS at 3-year: 46% and 60%, respectively) (P < 0.0001).
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Greece. Humans. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071488.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW Jr, Dien PY, Lyons R, Schlegel PJ, Vukelja SJ, Boston J, Boehm KA, Wang Y, Asmar L: Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood; 2010 Jan 21;115(3):475-80
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.
  • This study evaluated the efficacy and safety of single-agent bortezomib in indolent B-cell lymphoma that had relapsed from or was refractory to rituximab.
  • The median age was 70 years, 53% female, Ann Arbor stage III-IIIE (28%) and IV (65%); 43 patients (72%) had more than 2 prior regimens; and 6 patients went on to maintenance.
  • Median time to response = 2.2 months (range, 1.2-5.3 months); duration of response = 7.9 months (2.8-21.3 months); 1-year survival was 73% and 2-year survival was 58%; median survival = 27.7 months (range, 1.4-30.9 months); median progression-free survival = 5.1 months (range, 0.2-27.7 months), median time to progression = 5.1 months (range, 0.2-27.7 months), and median event-free survival = 1.8 months (range, 0.2-27.7 months).
  • Treatment-related grade 3 or 4 adverse events included: thrombocytopenia (20%), fatigue (10%), neutropenia (8.5%), and neuropathy and diarrhea (6.8% each).
  • This study demonstrates that bortezomib has modest activity against marginal zone and follicular lymphoma; it has the potential for combination with other agents in low-grade lymphomas.
  • Maintenance therapy should be explored further.
  • [MeSH-major] Boronic Acids / therapeutic use. Lymphoma, B-Cell / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bortezomib. Disease Progression. Drug Resistance, Neoplasm / drug effects. Female. Humans. Male. Middle Aged. Recurrence. Salvage Therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965689.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


20. Tsang RW, Gospodarowicz MK: Low-grade non-hodgkin lymphomas. Semin Radiat Oncol; 2007 Jul;17(3):198-205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common low-grade non-Hodgkin lymphomas are of B-cell origin.
  • This review will focus on follicular lymphomas and extranodal marginal zone lymphomas, also known as mucosa-associated lymphoid tissue (MALT) lymphomas.
  • Moderate doses (30-35 Gy) for these stage I and II low-grade lymphomas result in long-term local control and possible cure.
  • Involved-field radiation therapy is the standard approach and produces minimal morbidity.
  • For follicular lymphoma, this occurs in approximately 50% of patients after 15 years and for nongastric MALT lymphoma 30% to 40% after 10 years.
  • Patients with relapsed disease are not curable with chemotherapy, but the disease often remains indolent and prolonged survival is observed.
  • For gastric MALT lymphomas associated with Helicobacter pylori but which did not respond to antibiotic therapy, radiation treatment is indicated and almost always curative.
  • For localized MALT lymphomas not related to microorganisms, radiation therapy is the initial standard therapy regardless of anatomic location.
  • Patients with stage III and IV low-grade lymphoma and local symptoms are often successfully palliated with a low dose regimen of 2 x 2 Gy (total dose 4 Gy).
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Helicobacter Infections / radiotherapy. Helicobacter pylori / radiation effects. Humans. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell, Marginal Zone / microbiology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Follicular / radiotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Palliative Care. Prognosis. Radiotherapy Dosage. Stomach Neoplasms / microbiology. Stomach Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591567.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


21. MacDermed D, Thurber L, George TI, Hoppe RT, Le QT: Extranodal nonorbital indolent lymphomas of the head and neck: relationship between tumor control and radiotherapy. Int J Radiat Oncol Biol Phys; 2004 Jul 1;59(3):788-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-five were Stage I-IIE.
  • The most common histologies were marginal zone lymphoma and follicular grade 2.
  • Patients received combinations of surgery, chemotherapy, and radiotherapy.
  • Local therapy included surgery alone in 6 patients, radiotherapy alone in 7, and surgery plus radiotherapy in 12.
  • Improvement in freedom from progression with radiotherapy was statistically significant for Stage I-II patients (88% vs. 50%, p = 0.02) and of borderline significance in Stage III-IV patients (100% vs. 23%, p = 0.07).
  • Early use of radiotherapy resulted in significantly higher rates of freedom from progression and freedom from local progression in early-stage patients.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Lymphoma, Follicular / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Neoplasm Staging. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery. Radiotherapy Dosage. Retrospective Studies. Salivary Gland Neoplasms / drug therapy. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / radiotherapy. Salivary Gland Neoplasms / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15183482.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR: Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. J Chemother; 2009 Aug;21(4):434-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
  • This pilot study tested the hypothesis that dose intensity/dose density treatment may improve the response rate and remission duration in patients with advanced low grade lymphomas. ten patients with low grade lymphomas: follicular lymphoma grades I and II, marginal zone lymphoma, and small cell lymphocytic lymphoma with progressive disease were studied.
  • Patients had an ECOG performance of 0-2, and Stage III and IV disease.
  • Patients received a combination of rituximab 375 mg/m(2), cyclophosphamide 1000 mg/m(2), and vincristine 1.4 mg/m(2) (up to a maximal dose of 2 mg), administered by intravenous infusion every two weeks, for ten treatments.
  • Granulocyte colony stimulating factor (G-CSf) was administered on days seven to ten following each cycle of chemotherapy.
  • Untreated patients received an average of 8.3 cycles of therapy (range 5 to 10 cycles).
  • Previously treated patients received an average of 9.3 cycles of therapy (range 6 to 12 cycles).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prednisone / administration & dosage. Prognosis. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19622463.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 5-P30-CA 072720-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


23. Huang SS, Jou SH, Chiu NY: Catatonia associated with coadministration of tramadol and meperidine. J Formos Med Assoc; 2007 Apr;106(4):323-6
Hazardous Substances Data Bank. MEPERIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tramadol and meperidine are frequently prescribed medications in the management of oncologic patients.
  • The pharmacologic interaction of these two drugs may induce mental disturbance.
  • This was demonstrated by our case of a 39-year-old woman with gastric mucosa associated lymphoid tissue lymphoma (MALToma), stage III after chemotherapy.
  • Two days later, the patient developed transient visual hallucinations and disorientation after additional injection of meperidine (25 mg).
  • The duty doctor stopped all the medications.
  • From the clinical course, we suggest that the catatonia was caused by drug interactions between tramadol and meperidine.

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17475611.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 39J1LGJ30J / Tramadol; 9E338QE28F / Meperidine
  •  go-up   go-down


24. Kelessis NG, Vassilopoulos PP, Bai MP, Agnantis NJ, Avital SR, Rosenthal RJ: Update of the role of surgery in the multimodal treatment of MALT gastric lymphomas. Anticancer Res; 2002 Nov-Dec;22(6B):3457-63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update of the role of surgery in the multimodal treatment of MALT gastric lymphomas.
  • BACKGROUND: Primary gastric non-Hodgkin's lymphoma is a well-defined clinicopathological entity with a distinct histological spectrum and indolent course.
  • In this study we present our experience with surgery being part of the multimodal treatment and we compare our results with those referred to in the world literature.
  • MATERIALS AND METHODS: Sixty-five patients (37 males, 28 females) with gastric MALT lymphoma were retrospectively analyzed.
  • Forty-seven patients underwent curative resection, eleven received chemotherapy as primary treatment, two patients received radiotherapy before any other treatment and five patients received combined chemo-radiation therapy.
  • RESULTS: For the early stages of the disease (I-III), radical resection offered a two-year survival rate of 100% and 93%, respectively, and a five-year survival of 85% and 67%, respectively.
  • For those stage I patients, who were managed surgically followed by adjuvant therapy, the two- and five-year survival was 90% and 78%, respectively.
  • For stage II patients for whom chemo-radiation therapy followed surgery, the two- and five-year survival was 88% and 65%, respectively.
  • CONCLUSION: In view of the results of our study, surgery is an adequate treatment modality for the early stages of the disease.
  • The addition of radiotherapy or chemotherapy does not improve the overall survival.
  • Conversely, for the advanced stages (II2-IV), primary chemotherapy is the best treatment option with surgery being reserved for cytoreduction or chemo-radiotherapy-induced complications.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Gastrectomy / adverse effects. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pyloric Antrum / pathology. Pyloric Antrum / surgery. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12552939.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


25. Tari A, Asaoku H, Tani H, Kashiwado K, Kurihara K, Fujihara M, Yoshino T: [Evaluation of non-surgical therapy for the malignant lymphomas located mainly in the stomach and duodenum]. Nihon Shokakibyo Gakkai Zasshi; 2001 Oct;98(10):1154-63
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of non-surgical therapy for the malignant lymphomas located mainly in the stomach and duodenum].
  • We evaluated the effects of the conservative treatment to 29 patients with non-Hodgkin lymphomas located mainly in stomach and duodenum.
  • We could induce complete remission in all the cases of stage I, II, and III including MALT lymphomas by the combination therapy of Helicobacter pylori (H. pylori) eradication, chemotherapy, and radiation, and the complete remission persisted in all except for the three cases who died of other causes.
  • Even in stage IV lymphomas mainly located in stomach and duodenum, we could induce complete remission in 50% of them.
  • Considering the quality of life of patients with lymphomas located mainly in stomach and duodenum, the conservative treatment may be of benefit more than the surgical approach.
  • [MeSH-major] Duodenal Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Helicobacter pylori / isolation & purification. Humans. Lymphoma, B-Cell, Marginal Zone / therapy. Male. Middle Aged. Prednisone / administration & dosage. Radiotherapy Dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11680989.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down






Advertisement